Latest News

Nanobiotix

Nanobiotix got the all-clear for its new Phase I/II clinical trial

The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations for its lead product, NBTXR3. This could lead to an increase in the commercial potential of this promising French Biotech. Nanobiotix is a great French …

READ MORE →
Biogen_Switzerland

Biogen is back home with its $1Bn Swiss production plant

Biogen is coming back home. The American company is opening a production plant in Switzerland that will employee 400 professionals. To this aim, the company will invest €0.9Bn ($1Bn) into the project. Biogen was founded back in 1978 in Geneva, Switzerland, and now aims at expanding its manufacturing network by …

READ MORE →
roche_evotec

Roche and Evotec knocked down by their Alzheimer candidate

The progressive aging of the population in developed countries is turning Alzheimer into one of the biggest medical challenges of our times. And it looks like it is going to remain an unresolved problem for the moment, as Roche’s candidate failed its last clinical trial. The drug, developed in collaboration …

READ MORE →
traffic_labiotech_eul

Over 11500 Visitors in June, you’re amazing!

This morning, we looked at June’s statistics and you were over 11500 on Labiotech.eu this last month. And look at this graph that stands on our office door, our growth is really rapid and we reached our objective. That’s just amazing, you guys ROCK! I’m really excited that we are changing together …

READ MORE →
adocia_eli_lilly

Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster?

Adocia and Eli Lilly completed an impressive Phase Ib clinical trial evaluating BioChaperone Lispro, a treatment designed to accelerate insulin absorption. The study aimed to compare BioChaperone Lispro to Lilly’s Humalog in type 1 diabetes patients, the former being much more effective. Humalog, Lilly’s blockbuster, is about to be ousted by Adocia’s …

READ MORE →
alexion_Synageva

Two of Alexion’s rare-disease drugs get the thumbs up from the EU

The European Medicines Agency (EMA) is about to approve a couple of rare diseases drugs developed by Alexion. The two enzymes, Strensiq and Kanuma, received  positive feedback from the EMA’s Committee for Medicinal Products for Human Use, which normally leads to the approval of the drug. The Committee for Medicinal …

READ MORE →
curevac moderna

mRNA Therapies: CureVac Outperformed the Money Magnet Moderna

Everybody has already heard about Boston-based Moderna Therapeutics, the most highly valued venture-backed private Biotech, but CureVac, its German competitor, remains much more understated. This could rapidly change as CureVac just demonstrated that its technology beats Moderna‘s. mRNA technologies could theoretically disrupt the whole drug industry. Imagine that you can directly inject mRNA into patients to make them produce …

READ MORE →
TxCell

Green light for one of the largest clinical trials in Immunotherapy

In a period, where uncountable big pharmas and biotechs are struggling to get the largest piece of the immunotherapy cake, an unexpected player has arrived. TxCell, a French biotech, received an option to extend its current phase IIb study from EU to US, a stage that lots of immunotherapy experts would like to reach. …

READ MORE →
stallergenes

Stallergenes and Greer to create the World Leader in Allergy Immunotherapy

A few months ago, we were talking about the refusal of Stallergenes’ minority shareholders to merge with Greer laboratories, another competitor within the field of allergy treatment. Finally, Stallergenes shareholders accepted, and both companies are going to create the world leader in allergy immunotherapy. After the sale of Serono to Merck back in 2007, …

READ MORE →
Transgene

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Transgene, the oldest French Biotech company announced just yesterday that it will cut 120 jobs on its current 300 employees. The company will shut down its manufacturing facility in order to focus on the Research and Development of its therapeutic vaccine candidates. Wise move or final last words? Back in 1976, Robert …

READ MORE →
qiagen_vs_illumina_next_ngs_fight

Qiagen vs. Illumina, the next Big Fight in Next-gen Sequencing

Next-gen sequencing is a revolution. San Diego-based Illumina owns most of the market but German giant Qiagen is prepared to disrupt this fact by stepping in massively by the end of the year. The fight has only begun. Imagine you could sequence your genome to discover the disease you may have in the future. …

READ MORE →
actelion_Vaxxilon

Actelion & the Max Planck Society created the new leader in Synthetic Carbohydrate Vaccines

Actelion has created a new start-up in the field of synthetic carbohydrate vaccines, together with the Max Planck Society. Actelion has made a funding commitment of up to €30M to back the new company, Vaxxilon. Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and …

READ MORE →

Event Summaries

htc_xavier_duportet

Biotech & Medtech well represented at Europe’s largest technological start-up challenge

The second edition of the Hello Tomorrow Conference, a major event dedicated to disruptive technologies and science entrepreneurship, took place last week in Paris. This event gathered scientists, entrepreneurs and investors during two days to share & present the scientific innovations that will shape our future. It gathered 6 different scientific …

READ MORE →
bio2015_final_day

BIO2015: Over and Out!

Three is the magic number as they say… After bringing you the highlights of the first and second day of the biggest Biotech Convention worldwide, we couldn’t give up on you so close from the end. So without further ado, here’s the summary of day three. Katrine Bosley, CEO of Editas, hosted Arnt …

READ MORE →
Made with & in Berlin
Copyright ©, All Rights Reserved.
Designed and developped by Zelie Dethorey

ttt